Alnylam Pharmaceuticals Announces the Termination of its RNAi Collaboration with Merck
News Sep 20, 2007
Alnylam Pharmaceuticals, has announced that Merck & Co., Inc. ("Merck") and Alnylam have mutually agreed to terminate their July 2006 amended and restated RNAi agreement.
As a result, Alnylam has rescinded all grants of its intellectual property related to current and future Merck development programs, including the partnership's former co-development programs.
"It is fundamentally in our best interests to terminate our Merck collaboration," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. "We wish our colleagues at Merck the best of luck in their efforts."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.